General Electric to Acquire Ultrasound Technology Firm for USd 1.45 Billion. The industrial conglomerate will pay Altaris Capital Partners USD 1.45 billion in cash to take over BK Medical. The acquisition will help GE Healthcare expanding from diagnostics into surgical and therapeutic interventions

GE Healthcare

BK Medical

GE Healthcare acquired BK Medical for USD 1.45 billion to expand from diagnostics into surgical and therapeutic interventions, enhancing its ultrasound business

Pushing the envelope in MedTech with emerging technologies

Next-gen Medical Devices

Companies that develop surgical devices involving invasive interventions (cutting into a patient's body tissues) to treat, cure, or relieve a patient of an illness or disease

GE Healthcare moves imaging, clinical analytics platforms to Amazon Web Services cloud

Amazon Web Services

Signed an exclusive agreement for the manufacturing and distribution of iodine-123 (I-123) capsules in the United States

NorthStar Medical Radioisotopes

GE Healthcare and SOPHiA GENETICS collaborate to match treatments to multimodal patient data and cancer type

SOPHiA GENETICS

Ally Bridge Group

SoftBank Vision Fund

Cambridge Innovation Capital

Chimera Partners

Tencent

LGT group

Lightrock

Watrium AS

RPMI Railpen

PFM Health Sciences

CMR Surgical

To support healthcare providers in Cameroon, Côte d’Ivoire, Kenya, Rwanda, Senegal, Tanzania, and Uganda access essential medical equipment.

NSIA Bank

International Finance Corporation

GE Healthcare announced that it has acquired Zionexa and its molecular imaging agent

Zionexa

GE Healthcare announced it is acquiring Swedish start-up Prismatic Sensors AB, bolstering its key medical imaging business.

Prismatic Sensors AB

Announced a strategic partnership aimed at improving patient outcomes for the two biggest health burdens globally, cancer and heart disease.

genesiscare

Partnering on several clinical case studies to help build the platform and tools to accelerate AI projects.

Automation in clinical diagnostics to improve speed and accuracy in patient diagnosis and treatment.

Clinical Decision Support Systems

Pixyl

Software that provides a list of possible diseases based on data collected from patients. Platforms are only used for initial assessments.

AP-HP

TheraPanacea

Institut Curie

Institut Gustave Roussy

To enhance the mammography workflow, image management, and storage capabilities for the Senographe Pristina Mammography System.

Candelis

Collaborating to use Lunits's INSIGHT CXR and GE Healthcare’s Thoracic Care Suite to alleviate clinical strain among radiologists and improve patient outcomes

Membership-based, non-insurance healthcare companies helping maintain a steady state of well being.

Preventive Healthcare

Lunit

Tools that collect and analyze real-time patient data that supports healthcare providers with clinical decisions,  improves patient outcomes, and reduces medical errors.

To develop and test algorithms to aid in the diagnosis and management of COVID-19 pneumonia

University of Oxford

To create a database around chest imaging in patients suspected of being infected with SARS-Cov-2, the virus responsible for Covid-19.

Microsoft and GE Healthcare Partner to Launch Hospital Support Software

Microsoft

Sona Nanotech has announced a partnership with GE Healthcare Life Sciences to produce a rapid-response test for the Covid-19 coronavirus, which has sent Sona shares up into uncharted territory.

Sona Nanotech Ltd.

In collaboration with GE Healthcare Life Sciences, Biocompare has re-launched its next-generation sequencing (NGS) content hub called Future Lab

Biocompare

GE Healthcare Life Sciences entered into a strategic R&D and distribution partnership with Advanced Solutions Life Sciences got manufacturing personalized tissue regeneration.

Advanced Solutions Life Sciences

GE Healthcare, the medical equipment subsidiary of multinational conglomerate GE, and 3D printer provider Formlabs have announced a collaboration aiming to make it easier for clinicians to 3D print patient-specific anatomical models from imaging data.

Formlabs

More important now than ever, telehealth will long outlast the pandemic that drove its growth.

Telehealth

Decisio Health

Companies developing B2B software solutions for patient engagement, care navigation, practice management, and electronic health records integration to facilitate telehealth services for healthcare providers. 

Will be integrated into GE Healthcare’s Edison™ Open AI Orchestrator, which is designed to simplify the deployment of AI for imaging workflows.

MaxQ-AI

To develop a model to bring a same-day breast cancer diagnosis and treatment model to the United States.

Premier Inc

Entered into a global commercial partnership for a new Prostate-Specific Membrane Antigen (PSMA) PET/CT imaging agent.

Theragnostics

To deliver educational programming on biopharmaceutical and cell therapy development and manufacturing.

NIBRT

Collaborating to develop a fully integrated, expandable manufacturing solution for emerging biotherapeutics

Germfree Laboratories Inc

GE Healthcare partnered with Fujitsu to develop AI to help spot brain aneurysms

Fujitsu Australia

GE Healthcare will distribute and support the Nyansa Voyance AIOps platform for health care customers. The arrangement, for the first time, provides an advanced analytics solution for biomed and IT professionals to address the increasingly complex mission-critical networks and network-connected patient care devices.

Generating, collecting, and analyzing enterprise data will never be the same.

Edge Computing

Nyansa

Companies that provide software to enable users to run their applications at the edge.

GE Healthcare partners with Vanderbilt University to develop precision immunotherapy apps

Vanderbilt University

The partnership entails the development of an integrated tumor diagnosis dashboard

Roche

GE Healthcare partners with Boston Children’s for radiology-based AI dev

Boston Children's Hospital

To develop non-invasive Positron Emission Tomography (PET) imaging agents (tracers) targeting CD8, focused on marking cytotoxic T lymphocytes, key predictors of immunotherapy response.

Indi Molecular

Partnered with GE Healthcare to bring bring digital healthcare solutions to the market. The partnership will help GE Healthcare tap the healthtech start-up ecosystem in the country to co-create solutions for real-world healthcare challenges in the areas of digital applications for early detection, productivity solutions, and remote and connected care among others\

NASSCOM

Combining their automation, IT and single-use solution expertise to build bioprocessing operations for the digital age. The two companies will help biopharmaceutical companies create flexible and scalable facilities of the future, focused on rapid response to market demands, streamlined production technologies and adaptable manufacturing environments.

Automation to improve business efficiency

Workflow Automation Platforms

Rockwell Automation

Platforms that offer a range of workflow automation and RPA bots that are not specifically targeted at any business function

Announced a digital data exchange collaboration program with Amgen, which will include advanced data analytics to increase the understanding of the relationship between raw material variability and process performance during the manufacture of biologic medicines.

Amgen

Assist transform healthcare delivery and patient experience across the 21-hospital system in California, Oregon and Hawaii. During the next five years, the organizations will partner to maximize the capacity of the system’s clinical assets and leverage them to improve patient care delivery.

Adventist Health

To transform healthcare delivery and reduce the cost of care in central Georgia for the benefit of the local community. Over the course of the next six years, the two entities will work side by side to make system-wide improvements that will cover every aspect of care delivery and generate up to $150 million in improvements for Navicent Health.

Navicent Health

Partnered with Preventice Solutions to give clinician tools to follow patients with known or suspected Atrial fibrillation virtually from hospital to home.

Preventice Solutions

Houston medtech startup Decisio Health is partnering with GE Healthcare to accelerate a broader deployment of its critical care dashboard.

To improve cell therapy and viral vector manufacturing by providing drug developers with a combined, flexible, and readily deployable manufacturing platform suitable for early-stage clinical or commercial production.

G-CON Manufacturing

To develop more precise cancer immunotherapy diagnostics that use artificial intelligence to predict both efficacy and potential side effects.

University of Toledo

Cardinal Health

Stryker

Siemens Healthineers

Abbott

Johnson & Johnson

<div>
 
 Decisio Health is a technology service provider that facilitates remote patient monitoring and clinical monitoring support services. Its OpticsIQ solution helps clinicians enable remote patient monitoring and virtual consultations, consolidates and prioritizes real-time patient-related data from any device, and helps with identifying at-risk patients through its inbuilt analytics system. The platform, which is an FDA 510(k) Class II cleared medical device, can be focused on a single area of care or scaled across the entire health system. 
 
 
 The Texas-based company operates on a B2B basis, where it offers its solutions to healthcare providers and large hospital systems in the US. Decisio offers remote care providers access to real-time patient information from multiple sources, and combines this with the hospital&rsquo;s parameters and protocols. This information is used to support clinical decisions. 
 
 
 In March 2022, the company raised USD 18.5 million in a Series B funding round. The raised funds are to be used for commercialization, improving its platform and growing operations. This brings the total funds raised by the company to USD 31.5 million.
 
</div>

OhMD is a text-based digital platform that facilitates communication between healthcare providers and patients via SMS and video visits. The platform can be accessed by healthcare providers via desktop or mobile app. The mobile app is free to download and can be used by both doctors and patients.OhMD offers three service plans comprising Basic, Plus, and Reach. The Basic plan offers a free-to-use OhMD app for texting colleagues and patients, Plus is for clinical team communication and is priced at USD 7 per month per user while Reach provides access to telehealth, two-way texting, and patient relationship management. Features offered by OhMD text service also include broadcasts texts, forms, surveys, files, video visits, clinical &amp; team communication, website chat, and appointment reminders. As of February 2022, the platform had 400,000 providers onboard and the company reported a 101% YoY growth in revenue.The firm raised an undisclosed amount in a seed funding round led by FCA Venture Partners and Dudley Fund in February 2022. The last seed funding secured by the company was in March 2017, which was also undisclosed. The funds are earmarked for adding innovative solutions to its platform and strengthening patient relationships by facilitating communication between patients and healthcare providers including practices, hospitals, and health systems across all healthcare specialties. It also intends to enter into new strategic partnerships with healthcare providers to enhance communication.

CMR Surgical is a prominent medical device company specializing in robotic-assisted surgery. The company has developed Versius, a small, modular, and versatile surgical robotic system designed to assist surgeons in complex soft tissue surgeries. Its portable design allows seamless integration into hospital workflows, enabling high utilization across multiple surgical departments. The system's modularity allows surgeons to use only the required number of arms for a specific procedure, optimizing port placement and facilitating precise and accurate movements through its fully-wristed instruments and 3D HD vision.Versius has been utilized for a wide range of procedures, including prostatectomies, abdominal wall repairs, hysterectomies, proctocolectomies, esophagectomies, and lobectomies. It has also been employed in combined operations such as endometrial tissue removal, rectopexy, ureteroplasty, fundoplication with Nissen's technique, gastric bypass, and cholecystectomy. As of March 2024, over 20,000 surgical cases were completed using Versius globally, with over 160 installations worldwide.In addition to its surgical capabilities, Versius incorporates a digital ecosystem that captures meaningful data to support surgeons' continuous learning. Through the Versius Connect app, Versius Trainer, and the CMR clinical registry, the system provides insights to improve surgical care.&nbsp;CMR Surgical's Versius global install base grew by more than 50% from 2022 to January 2024.Key customers and partnershipsCMR Surgical primarily targets hospitals, surgeons, and teams seeking advanced robotic-assisted surgical systems. The company has established partnerships with renowned hospitals globally, including Royal Papworth Hospital NHS Foundation Trust, Addenbrooke's Hospital, Milton Keynes University Hospital, NHS Foundation Trust, Institut Curie, Policlinico di Milano, Max Super Specialty Hospital, the Sindh Institute of Urology and Transplantation, Hospital Moinhos de Vento, Gleneagles Hospital, Klinikum Chemnitz GmbH, The Wellington Hospital, and Rotenburg Hospital.&nbsp;In September 2022, CMR Surgical partnered with Surgical Innovations to develop YelloPort Elite 5mm, a new surgical port access system designed for Versius. In November 2023, it partnered with Ledidi to develop a clinical registry platform that enhances data-driven clinical practice.

MediView is a Cleveland-based medtech company that leverages augmented reality (AR), remote connectivity, and spatial computing to create revolutionary surgical navigation and teleprocedure platforms. Its core technology combines AR visualization with surgical navigation to provide surgeons and healthcare professionals with 3D "X-Ray vision" through the skin for minimally invasive procedures.MediView's flagship product, the XR90 Augmented Reality Surgical Navigation System, received FDA 510(k) clearance in July 2023. It empowers practitioners with a holographic view of the patient's detailed internal soft tissue, organ, vascular, and skeletal structures. The system also combines live imaging and tracking of the surgeon's tools with the X-ray vision for comprehensive surgical navigation capabilities. The XR90 platform's first application is expanding access to less invasive cancer ablation therapies.Additionally, MediView offers the XR30 and XR50 solutions. The XR30, commercially available, alleviates ergonomic challenges by enabling practitioners to optimally position ultrasound imaging in their line of sight during procedures and facilitates remote collaboration. The XR50 adds procedural guidance capabilities to the XR30 by creating a visible pathway for the practitioner's instrument.MediView's products were developed in collaboration with Microsoft, utilizing the HoloLens two AR headset, and GE healthcare, utilizing their imaging technologies. Clinical and technical research was conducted at the Cleveland Clinic. As of March 2024, the XR90 system demonstrated statistically significant target registration error (TRE) and image fusion registration error (IFRE) metrics, providing evidence of its accuracy for clinical applications.Key customers and partnershipsMediView has formed strategic partnerships with leading organizations in the healthcare industry, including Microsoft and GE healthcare. In November 2022, MediView and GE healthcare announced their collaboration to co-develop the OmnifyXR Interventional Suite System. This solution integrates GE's imaging technologies with MediView's AR and surgical navigation expertise, enabling clinicians to evaluate multiple holographic displays of live imaging in 3D using Microsoft's HoloLens technology.

<div>
 
 AliveCor is an AI-enabled remote patient monitoring company that develops mobile electrocardiogram (ECG) devices that track users&rsquo; heartbeats under its flagship brand KardiaMobile.
 
 
 The FDA-approved solution is built on its proprietary technology, AI/ML-powered ECG sensors, and enables the detection of various cardiac conditions, such as atrial fibrillation, bradycardia, tachycardia, and sinus rhythm with supraventricular ectopy, in 30 seconds.&nbsp;
 
 
 The company&rsquo;s cardiological care subscription services include 1) KardiaCare, which offers heart health insights and monitoring features, including unlimited ECGs and clinician review at USD 11.99 per month, and 2) KardiaPlus, which extends the KardiaCare membership with additional reviews, a KardiaMobile 6L device, and blood pressure cuff.&nbsp;&nbsp;
 
 
 Key customers and partnerships
 
 
 As of January 2024, the company had served more than two million customers in over 40 countries.
 
 
 The company has several key partners. These include the following:&nbsp;
 
 
 - Clario to enable ECG readings to be collected from trial participants&rsquo; homes (
 <a href="https://sp-edge.com/updates/21063">
 August 2023
 </a>
 )
 
 
 - Thomas Jefferson University Hospital to evaluate the benefits of QTc monitoring with KardiaMobile 6L for patients receiving methadone maintenance therapy for opioid use disorder (
 <a href="https://www.prnewswire.com/news-releases/alivecor-and-thomas-jefferson-university-hospital-partner-to-evaluate-kardiamobile-6l-for-qt-prolongation-screening-in-patients-treated-for-opioid-use-disorder-301881575.html">
 July 2023
 </a>
 )
 
 
 - PaceMate to create an integrated system that will facilitate the collection and evaluation of ECG data (
 <a href="https://www.medicaldevice-network.com/news/cardiac-monitoring-pacemate-alivecor/">
 May 2023
 </a>
 )
 
 
 - BIOTRONIK to combine BIOTRONIK's injectable cardiac monitor with AliveCor's ECG technology (
 <a href="https://www.prnewswire.com/news-releases/biotronik-announces-collaboration-with-alivecor-as-first-in-a-series-of-strategic-partnerships-to-disrupt-cardiac-digital-health-with-ai-enabled-solutions-301620650.html">
 September 2022
 </a>
 )
 
 
 - GE Healthcare to integrate ECG data from AliveCor's KardiaMobile 6L device directly into GE Healthcare&rsquo;s MUSE Cardiac Management System for physicians to view and evaluate (
 <a href="https://www.businesswire.com/news/home/20220316005427/en/GE-Healthcare-AliveCor-Partnership-Aims-to-Increase-Convenience-for-Patients-and-Help-Reduce-Cardiac-Related-Hospitalizations-by-Improving-the-Quality-and-Integration-of-Patient-Data">
 March 2022
 </a>
 )
 
 
 - AstraZeneca to study disease management solutions using AliveCor&rsquo;s Kardia-K technology (
 <a href="https://sp-edge.com/updates/2136">
 February 2021
 </a>
 )
 
 
 Funding and financials
 
 
 In 
 <a href="https://sp-edge.com/updates/12459">
 August 2022
 </a>
 , the company raised an undisclosed amount in a Series F funding round led by GE Healthcare. The funds were aimed at advancing its cardiological care subscription services. 
 
</div>

Technologies bringing about a new reality

Extended Reality

MediView is a MedTech company that leverages AR, telecollaboration, and data-driven insights to improve diagnostic imaging, surgical navigation, and clinical efficiencies. MediView's remote connectivity enables medical professionals to connect and collaborate remotely through shared communication, visualization, and holographic guidance. Moreover, MediView records the data generated during holographic procedures to provide insights to medical professionals. In addition, Mediview offers a training environment for students at sonography and echo programs, nursing schools, physician assistant schools, medical schools, and veterinary schools.The company provides three solutions, MediScout (XR30), MediView XR50, and MediView XR90, at various stages of development. MediScout is a commercially available FDA Class I medical device, offering a collaborative and ergonomic ultrasound imaging solution. The XR50, to be submitted for FDA clearance, is an ultrasound imaging solution for needle-based procedures. The XR90, MediView's flagship product, is an FDA cleared imaging and navigation system for soft tissue and bone procedures, providing a clear view of the patient's internal anatomy via holographic surgical navigation (3D x-ray vision). In March 2024, a study published on the Journal of Medical Imaging found the XR90 accurate enough to carry out procedures with clinical precision.Key customers and partnershipsMediView provides its solutions in partnership with GE Healthcare and Microsoft by integrating Microsoft's HoloLens 2 head-mounted display and GE's Vivid iq ultrasound system. In November 2022, Mediview collaborated with GE to develop the OmnifyXR Interventional Suite System, which is intended to improve ergonomics with natural interactions for optimum workflow and facilitate care team cooperation. In June 2024, MediView announced the first successful clinical use of the platform.Funding and financialsIn <a href="https://sp-edge.com/updates/18603">May 2023</a>, the company raised USD 15 million in a strategic funding round with participation from Mayo Clinic, Cleveland Clinic, and GE HealthCare, among others. Funds were earmarked to create and enhance the company’s multi-level platform, prioritizing activities such as generating more clinical evidence, developing new products, protecting intellectual property, meeting regulatory requirements, achieving commercial goals, and launching new products.

Decisio Health is a Houston-based digital health company that offers a clinical decision support platform designed to aggregate and prioritize real-time patient data from various sources and present it visually in a single place. Their flagship product, InsightIQ, utilizes continuous smart bedside monitoring to enable clinical teams to efficiently identify at-risk patients and comply with established clinical guidelines. InsightIQ improves patient outcomes, optimizes workflow, increases collaboration, reduces length of stay, and alleviates "click fatigue."
InsightIQ is a decision support device that aggregates, displays, and manages physiological and other patient information generated by third-party medical devices and patient information systems. The software performs automated calculations on patient data collected by third-party devices based on approved clinical protocols at patient care facilities. It is designed to display patient information, facility-specific care protocols, and visual cues to care providers on a single display device, receiving data through the facility's Electronic Medical Record system.
In March 2022, Decisio Health appointed Major General Elder Granger to its board of directors to leverage his expertise in the healthcare industry. The company closed an USD 18.5 million Series B funding round in February 2022, bringing the total funds raised to USD 31.5 million since its founding in 2013. In May 2022, Decisio Health gained a patent (US Patent 11,309,079B2) related to a system, method, and computer program product for providing a patient dashboard system in a hospital setting. The company also rebranded, with the InsightIQ product previously known as DECISIOInsight.
In September 2022, Decisio Health received the Houston Business Journal's Innovation Awards, recognizing its innovative approach to improving patient outcomes and reducing costs through digitized bundles of care.

Radioactive materials open up new pathways in patient treatment and medication

Radiopharmaceuticals

Nucleus RadioPharma is a contract development and manufacturing organization (CDMO) dedicated to the development and manufacturing of targeted radiotherapies. Founded in 2022 by Eclipse Ventures and Mayo Clinic, the company aims to address the challenges faced in the production and supply chain of radiopharmaceuticals. These specialized drugs offer a highly targeted approach to various cancer types and stages, with the potential to treat many cancers.
Nucleus RadioPharma's core mission is to ensure cancer patients can access potentially lifesaving radiopharmaceuticals by developing technologies to modernize the clinical development, manufacturing, and supply chain processes. The company's innovative approach involves establishing multiple large regional manufacturing facilities across the US. The first facility, spanning 12,000 square feet, is located near the Mayo Clinic in Rochester, Minnesota, and is expected to be operational by mid-2024.
To enhance its manufacturing capabilities, Nucleus RadioPharma has secured a USD 56 million Series A funding round led by Eclipse and GE healthcare, with participation from other investors such as Mayo Clinic and Fox Chase Cancer Center. This funding will enable the establishment of additional manufacturing sites and the development of novel technologies for the production, distribution, and delivery of radiopharmaceuticals.
Nucleus RadioPharma's technology platforms are designed to advance new therapies through clinical trials to commercialization. The company provides a range of services, including formulation development, analytical method development, regulatory documentation, and drug product manufacturing. Its flexible approach allows for multiple onboarding points to accommodate innovators at various stages of their product lifecycle.
In November 2023, Nucleus RadioPharma partnered with SHINE Technologies, the largest producer of lutetium-177 in North America, to secure a long-term supply of this vital component for targeted radiopharmaceutical treatments. This agreement ensures a reliable and consistent supply of lutetium-177, a crucial element in cutting-edge medical treatments for neuroendocrine tumors and prostate cancer.

Molecular Assemblies is a San Diego-based company developing a revolutionary, enzymatic DNA synthesis technology capable of powering new products in industrial synthetic biology, personalized therapeutics, precision diagnostics, and eventually information storage, nanotechnology and more. Inspired by nature, the company’s proprietary DNA synthesis method is designed to produce long, high quality, sequence-specific DNA reliably, affordably and sustainably. With a highly experienced executive and scientific team and an expansive intellectual property portfolio, Molecular Assemblies has attracted investments from Agilent Technologies, Cavendish Impact Capital Fund, Data Collective Venture Capital, Eleven Two Capital, Genomics Investment Syndicate, Keshif Ventures, Newport Holdings, LP, and Alexandria Venture Investments.

Laza Medical is a privately held startup focused on producing a high-quality AI-powered robotic imaging solution for cardiovascular treatments.

Nucleus RadioPharma is a new company that was founded to ensure that cancer patients have access to potentially life-saving radiopharmaceuticals by developing technologies to modernise the clinical development, manufacturing, and supply chain of these promising new therapies.

MediView XR is a MedTech company developing augmented reality x-ray vision for surgery, remote collaboration, and data-based insights. The company also designs intellectual property in development of Extended Reality Surgical Navigation with intended use in the ablation and biopsy of cancerous tumors.

AliveCor has a device and application that will turn any smartphone into a clinical-quality electrocardiogram (ECG) recorder. AliveCor is pioneering the creation of FDA-cleared 'machine learning' techniques to enable proactive heart care and is recognized around the world for transforming cardiac care. It specializes in the fields of healthcare, mobile device, and medicine. It was founded in 2010 and headquartered in Mountain View, California.

Centerline Biomedical, Inc. was founded in November 2014 and is based on technology developed at the Cleveland Clinic. Centerline's mission is to develop advanced navigation systems that initially target interventional vascular procedures.

Pulsenmore is the emerging leader in connected at-home ultrasound, delivering convenience and efficiency beyond traditional in-facility imaging. Our unique handheld ultrasound scanner docks with the patient’s smartphone to deliver high quality images that can be created anywhere, stored and forwarded for clinical review or shared in an online consultation. Founded in 2015, Pulsenmore is based in Omer, Israel and is privately held.

OhMD is a leading conversational patient engagement software that enables HIPAA compliant SMS and RCS text-based patient communication for medical practices helping to eliminate phone tag and improve the patient experience.

CMR Surgical develops a surgical robotic system for minimal access surgery. It makes minimal-access surgery universally accessible and affordable by significantly expanding the range of procedures that robots can perform and allowing surgeons to access 3D high-definition imagery and feedback during the operation.

Decisio Health is a helping care providers reach accurate decisions quickly and easily.The company's platform focuses on the availability of vital patient data, unprecedented automation, and premier analytics by aggregating disparate data to transparently close the gaps, offering organizations to have an opportunity to identify and correct areas of operational deficiencies, enabling clinicians to monitor patients on a single screen easily accessible from compatible web browsers.

SonoSim creates a portable, laptop-based ultrasound training system that makes learning ultrasonography more accessible by a wider audience.

InSightec is the pioneer and global leader in MR guided focused ultrasound technology for image guided acoustic surgery.  ExAblate® 2000 system was the first system to use the MR guided focused ultrasound technology. The ExAblate system received CE mark in 2002 and the Food and Drug Administration (FDA) approval in 2004 for the treatment of symptomatic uterine fibroids. ExAblate received the European CE Mark for pain palliation of bone metastases in June 2007 and for adenomyosis in June 2010. This device has won numerous innovation awards and has been used to treat thousands of patients around the world.

Adavium Medical is a medical equipment and diagnostics company aimed at bringing commercial sophistication to a highly fragmented market. The Company was formed with the intent to commercialize the most innovative portfolio of medical device and diagnostics products in Brazil. Adavium Medical portfolio today is made up of products that we commercialize on behalf of leading international companies. Adavium Medical assembled an experienced team of more than 300 employees that ensure that its fully-integrated commercial platform operates at world-class standards. Adavium Medical have the largest customer base across premium and “long tail” customers of any medical equipment and/or diagnostics company in Brazil, with more than 2,500 customers respectively in medical equipment and diagnostics. This is exponentially more than the average distributor or multinational in the region. The company was founded in 2011 and is headquartered in Sao Paulo, Brazil.

Check-Cap is a young and dynamic medical device company with breakthrough solution for Colorectal Cancer Screening. The Check-Cap device requires no bowel preparation or invasive procedures, and is expected to detect clinically significant polyps within the same range of accuracy as a standard colonoscopy.

C8 MediSensors, Inc., a San Jose, CA-based developer of non-invasive continuous glucose monitors for diabetic patients.

NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research and molecular diagnostics. The company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications. NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection, and in 2013 launched Prosigna®, its first in vitro diagnostic product for prognosis of early stage breast cancer.

EKR Therapeutics, Inc., a specialty pharmaceutical company, focuses on acquiring, developing, and commercializing prescription products and oncology supportive care. It focuses on various areas, including oral mucositis, stomatitis, dry mouth/xerostomia, nutritional issues, cachexia, skin reactions, bone marrow depression, bone complications, acute and chronic pain, nausea, vomiting, and diarrhea. The company was founded in 2005 and is based in Bedminster, New Jersey.

Optherion, Inc., a biotechnology company, develops diagnostic and disease-modifying therapeutics for the management and treatment of early-stage age-related macular degeneration, dense deposit disease, atypical hemolytic uremic syndrome, and other chronic diseases involving the alternative complement cascade. The company was founded in 2005 and is based in New Haven, Connecticut.

CASI Pharmaceuticals, Inc. (''CASI'', ''we'' or ''us'') is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. CASI is focused on acquiring, developing and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. CASI is executing its plan to become a biopharmaceutical leader by launching medicines in the greater China market leveraging CASI's China-based regulatory and commercial competencies and its global drug development expertise.

SpinalMotion is dedicated to preserving motion in the spine for patients with degenerative disc disease. By developing innovative artificial discs and instrumentation, we seek to combine the kinematics of a mobile bearing design with materials designed for low wear and improved longevity. Building upon our international clinical experience since 2002, SpinalMotion obtained FDA approval to conduct lumbar and cervical artificial disc clinical trials in the United States in 2005.  SpinalMotion is a private company founded in 2004 by Southern Medical, a spinal implant company in South Africa, and Thomas Weisel Healthcare partners. Three Arch Partners became an investor in 2005, and in 2006 Skyline Ventures and MedVenture Associates joined the company's investor group.

Inverness Medical (now known as Alere Inc.) is a global provider of advanced consumer and professional medical diagnostic products for a range of disease states and conditions.  The company develops new capabilities in diagnosis, monitoring, and health management for sectors such as cardiovascular, respiratory, diabetes, toxicology, autoimmunity, clinical, women’s health, and more.    Additionally, Inverness Medical offers services for chronic care, wellness, case management, women’s health, home monitoring, research, evaluation, and training.   Since 2005, Inverness Medical has acquired nearly 20 companies, collectively creating the largest product portfolio in the industry.   Inverness Medical is headquartered in Waltham, Massachusetts, USA.

GE Healthcare provides medical technology, intelligent devices, and care solutions. They offer medical imaging, information technologies, medical diagnostics, patient monitoring systems, performance improvement, drug discovery, and biopharmaceutical manufacturing technologies. GE Healthcare's mission is to improve patient care and outcomes by providing innovative healthcare solutions. Their technologies are used in hospitals, clinics, research institutions, and pharmaceutical companies worldwide to diagnose and treat various medical conditions.

<div> GE Healthcare Technologies Inc. (NASDAQ: GEHC) provides digital infrastructure, data analytics, and decision support tools to help in the diagnosis, treatment, and monitoring of patients. It is one of the largest medical technology companies in the world, <a href="https://jobs.gecareers.com/healthcare/global/en/locations"> operating in more than 160 countries </a> . GE Healthcare was originally a subsidiary of General Electric Company (GE), before being spun off and listed on the Nasdaq in January 2023. GE Healthcare generated revenue of USD 19.5 billion in 2023. GE Healthcare operates revenue under four segments: Imaging, Ultrasound, Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment is the largest (~54% of total revenue in 2023) and offers X-ray units, CT and MR scanners, molecular imaging, and other image-guided therapies. The Ultrasound segment offers both general and special-purpose ultrasound devices. The PCS and PDx segments provide a range of diagnostic medical devices and pharmaceuticals, respectively. The US is GE Healthcare's largest market, contributing to ~42% of total revenue in 2023, followed by China (~13%). The company&rsquo;s medium-term strategic focus is on margin improvement; specifically to increase the adjusted EBIT margin to between the high teens and 20% (from 18%&ndash;15.1% in 2021&ndash;2023). GE Healthcare also expects to reach net-zero status by 2050. </div>

GE Healthcare initiated with Neutral at J.P. Morgan (NASDAQ:GEHC)

Companies that develop diagnostic devices used in a hospital setting to identify a disease, condition, or injury, such as imaging systems and endoscopes

Companies that develop implantable medical devices designed to be surgically placed inside the human body, either temporarily or permanently, including devices such as pacemakers, artificial joints, stents, and cochlear implants

Companies that develop non-surgical devices that are used in a procedure or intervention to cure or relieve a patient from an illness or disease such as laser treatments, dental equipment, and wound care management

Companies that develop monitoring devices that are used in a hospital setting to measure patient vital signs and ensure patient well-being post-treatment, such as cardiac and respiratory monitoring systems

Providers of software that enhances the functionality of medical device hardware (diagnosis, treatment, and monitoring)

Companies that develop devices to administer pharmaceutical substances into a patient's body, ensuring controlled release or targeted delivery, specifically for use in clinical settings to treat or manage medical conditions effectively

Providers of software that helps manage risks, ensure quality, and streamline audit processes during medical device development

Companies that use radioactive isotopes to develop medication for the treatment of diseases in patients.

Companies that use radioisotopes to develop solutions for the diagnosis of patients. Solutions are typically synthesized for internal use on patients and are employed in tandem with a diagnostic imaging device to identify disease or causes of diseases.

Companies that produce and supply radioisotopes to pharmaceutical companies creating radiopharmaceuticals.

Companies providing support services to radiopharmaceutical-related companies. These include testing services, research, and training.

Bringing Life-Saving Biologics to More Patients

Biosimilars

Biotechnology companies that focus on the research, development, production, and commercialization of prescription drugs including biosimilars.

Biotechnology companies that focus on the research, development, production, and commercialization of biosimilars based on original biological medicine.

Companies offering R&D capabilities and production facilities to biosimilar companies on contracts or partnerships.

Biopharmaceutical technology development and support service companies that offer specialized solutions to biosimilar companies.

Companies offering testing solutions to support the biological characterization, comparability, and other clinical assessments required in the biosimilar development process.

Leveraging personal data for custom-fit diagnosis and treatment

Precision Medicine

INCUMBENTS_PRESENT

PROMINENT_CATEGORY

<div>
 At the Society of Nuclear Medicine and Molecular Imaging (SNMMI), GE HealthCare unveiled a collection of precision care tools designed to help healthcare providers tackle the issues of accessibility concerning personalized medicine technology.
 Among the products released are the MINItrace Magni, a small and affordable cyclotron designed for the in-house production of PET tracers and radiometals to aid diagnosis. Additionally, GE HealthCare plans to expand its "Omni" platform with the Omni Legend 21 cm, a high-performance PET/CT system that provides services in various care areas and reduces imaging dose while maintaining high quality. The designs of both systems prioritize accessibility and scalability. The Omni Legend Mobile was also introduced as a portable PET/CT solution, making the Omni Legend system accessible to local hospitals.
 As a specialist in diagnostic imaging systems, ultrasound, patient monitoring, and healthcare IT solutions, GE HealthCare works to improve patient care and operational efficiency for healthcare providers. Furthermore, the company supplies pharmaceutical diagnostics, such as contrast media and molecular imaging agents, to aid advanced imaging procedures.
 
</div>

GE Healthcare

Featured Industries

EDGE Insights

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless